KMDA Q3 2025 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$520M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$47M+12.6% YoY

Gross Profit

$20M42.0% margin

Operating Income

$8M16.6% margin

Net Income

$5M11.3% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$7M

Stock-Based Comp.

$117,000

Balance Sheet

Total Assets

$377M

Total Liabilities

$112M

Stockholders' Equity

$265M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$42M	+12.6%
Gross Profit	$20M	$17M	+14.7%
Operating Income	$8M	$5M	+47.6%
Net Income	$5M	$4M	+37.1%